Division of Cardiovascular Medicine, University of Tennessee, Memphis; Gulf Coast Medical Center, Panama City, FL.
Division of Cardiovascular Medicine, University of Tennessee, Memphis.
Am J Med. 2019 Nov;132(11):1295-1304.e3. doi: 10.1016/j.amjmed.2019.05.015. Epub 2019 May 31.
The role of aspirin for primary prevention of cardiovascular diseases remains controversial, particularly in the context of contemporary aggressive preventive strategies.
Relevant randomized clinical trials were included, and risk ratios (RRs) were calculated using random-effects models. Additional moderator analyses were performed to compare the pooled treatment effects from recent trials (those reported after the guidelines of the National Cholesterol Education Program Third Adult Treatment Panel were published in 2001; thus, conducted on the background of contemporary preventive strategies) to the results of older trials.
Data from 14 randomized controlled trials involving 164,751 patients were included. Aspirin use decreased myocardial infarction risk by 16% compared with placebo (RR 0.84; 95% confidence interval [CI], 0.75-0.94); however, in the moderator analyses, aspirin was not associated with a decreased risk of myocardial infarction in recent trials, but was in older trials (P-interaction = .02). Overall, aspirin use significantly increased the occurrence of major bleeding (RR 1.49; 95% CI, 1.32-1.69) and hemorrhagic stroke (RR 1.25; 95% CI, 1.01-1.54). In moderator analyses, the risk of major bleeding (P-interaction = .12) or hemorrhagic stroke (P-interaction = .44) with aspirin was not significantly different between the older and new trials. Differences between aspirin and placebo in the risks for all-cause stroke, cardiac death, and all-cause mortality were not found.
In the context of contemporary primary prevention guidelines, the effect of aspirin on myocardial infarction risk was significantly attenuated, whereas its major bleeding and hemorrhagic stroke complications were retained. Therefore, in contemporary practice, routine use of aspirin for the primary prevention of cardiovascular events may have a net harmful effect.
阿司匹林在心血管疾病一级预防中的作用仍存在争议,尤其是在当代积极的预防策略背景下。
纳入了相关的随机临床试验,并使用随机效应模型计算风险比(RR)。进行了额外的调节因素分析,以比较最近试验(即 2001 年《国家胆固醇教育计划成人治疗专家组第三版指南》发布后报告的试验,因此是在当代预防策略背景下进行的)的汇总治疗效果与较旧试验的结果。
纳入了 14 项涉及 164751 名患者的随机对照试验的数据。与安慰剂相比,阿司匹林可使心肌梗死风险降低 16%(RR 0.84;95%置信区间 [CI],0.75-0.94);然而,在调节因素分析中,阿司匹林与最近试验中心肌梗死风险降低无关,但与较旧试验相关(P 交互 =.02)。总体而言,阿司匹林的使用显著增加了大出血(RR 1.49;95% CI,1.32-1.69)和脑出血(RR 1.25;95% CI,1.01-1.54)的发生。在调节因素分析中,阿司匹林在大出血(P 交互 =.12)或脑出血(P 交互 =.44)方面的风险在新旧试验之间没有显著差异。未发现阿司匹林与安慰剂在全因卒中、心脏死亡和全因死亡率方面的风险差异。
在当代一级预防指南的背景下,阿司匹林对心肌梗死风险的影响明显减弱,但其大出血和脑出血并发症仍然存在。因此,在当代实践中,阿司匹林常规用于心血管事件的一级预防可能会产生净有害影响。